...Good morning and welcome to the -- or good afternoon, I should say, and welcome to the 2021 Stifel healthcare conference. My name is Neil Carnahan. I am a research associate here at Stifel. This afternoon, I have the pleasure of introducing Dr. Pete Salzmann, CEO of Immunovant, the clinical-stage company focused on developing autoimmune therapeutics with a lead product candidate, IMVT-1401, a novel fully human anti-FcRn monoclonal antibody being developed in IgG antibody-mediated autoimmune diseases. We have a question box at the bottom of your screen if you want to send there any questions. You can also reach me over email, neil.carnahan -- my name is in the bottom left of my screen -- @stifel.com. With that, Dr. Salzmann, I'll let you to take it away. Pete Salzmann ...